FDA approves new breast cancer treatment for patients with a specific genetic mutation
On Jan. 12, the U.S. Food and Drug Administration (FDA) expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients…
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.